CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
Status:
Recruiting
Trial end date:
2025-05-31
Target enrollment:
Participant gender:
Summary
Currently there is no clinical biomarker that can be used to select patients for
CCR2-targeted therapy and to monitor response to such therapy. Considering the toxicity and
the rate of response to CCR2-targeted therapy, it is crucial to be able to identify patients
who may not response to this therapy in order to avoid the morbidity and expense associated
with ineffective therapy.
Therefore, the combination of the novel CCR2 imaging agent with the novel CCR2-targeted
therapy in this trial is of great importance to promote science while prolonging the life and
its quality in patients with PDAC. The investigators also believe that this combination will
make substantial contributions to the fields of cancer immunotherapy and tumor
monocyte/macrophage biology. Moreover, this imaging agent has the potential to not only
facilitate development and testing of future CCR2-targeted therapeutic agents but also serve
as a prescreen tool to select appropriate patients for imaging guided treatment.